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Abstract
Objective To determine whether a three day burst of
a potent corticosteroid is more effective than a mild
preparation used for seven days in children with mild
or moderate atopic eczema.
Design Randomised, double blind, parallel group
study of 18 weeks’ duration.
Setting 13 general practices and a teaching hospital
in the Nottingham area.
Participants 174 children with mild or moderate
atopic eczema recruited from general practices and
33 from a hospital outpatient clinic.
Interventions 0.1% betamethasone valerate applied
for three days followed by the base ointment for four
days versus 1% hydrocortisone applied for seven days.
Main outcome measures Primary outcomes were
total number of scratch›free days and number of
relapses. Secondary outcomes were median duration
of relapses, number of undisturbed nights, disease
severity (six area, six sign atopic dermatitis severity
scale), scores on two quality of life measures
(children’s life quality index and dermatitis family
impact questionnaire), and number of patients in
whom treatment failed in each arm.
Results No differences were found between the two
groups. This was consistent for all outcomes. The
median number of scratch›free days was 118.0 for the
mild group and 117.5 for the potent group (difference
0.5, 95% confidence interval − 2.0 to 4.0, P = 0.53).
The median number of relapses for both groups was
1.0. Both groups showed clinically important
improvements in disease severity and quality of life
compared with baseline.
Conclusion A short burst of a potent topical
corticosteroid is just as effective as prolonged use of a
milder preparation for controlling mild or moderate
atopic eczema in children.
Introduction
Atopic eczema, or atopic dermatitis, is an itchy inflam›
matory skin disorder that affects around 15% of British
school children.1 In most children the disease follows a
chronic relapsing course, and most children are
managed in primary care.1 2 Although topical cortico›
steroids have been the mainstay of treatment for the
past 40 years, few clinical trials have studied their opti›
mum use.3 Side effects such as thinning of the skin can
occur with these preparations. This causes anxiety for
both patients and clinicians and is the main reason for
patients’ poor compliance with treatment.4 5
A recent systematic review of treatments for atopic
eczema identified 83 randomised controlled trials
dealing primarily with topical corticosteroids.6 Most
trials lasted less than six weeks. None were conducted
in primary care, and most compared a new
preparation with an established preparation, rather
than addressing key issues such as duration of use,
potency, and cotreatment.7
To achieve prolonged remission of atopic eczema
many dermatologists use potent topical corticosteroids
in short bursts followed by a break period with a bland
emollient.8–10 Others advocate a mild preparation, such
as 1% hydrocortisone as required, to avoid local side
effects such as thinning of the skin.
We aimed to determine whether a three day burst
of a potent topical corticosteroid was more effective
than a mild preparation used continuously for seven
days, without causing an increase in thinning of the
skin. We also determined the costs of these treatment
regimens to the NHS.
Methods
Participants
We enrolled children aged 1 to 15 years with atopic
eczema as defined by Hanifin and Rajka’s modified
diagnostic criteria.11 We included patients that had had
mild or moderate atopic eczema within the past
month.12 Children with severe eczema were excluded
on ethical grounds. Other reasons for exclusion were
known sensitivity to the study treatments or eczema
confined to the face or nappy area.
We had intended to recruit children from
dermatology outpatient clinics at the three teaching
hospitals in the Trent region, but in order to meet
recruitment targets we also enrolled children from the
community. Participants were subsequently recruited
from the eczema clinic at Queen’s Medical Centre and
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from 13 general practices in the Nottingham area. Par›
ticipants recruited from the community were identified
through doctors’ records on the basis of a diagnosis of
eczema or the use of topical corticosteroids in the past
year. We assessed children from the community at their
doctors’ surgery and hospital patients at the Queen’s
Medical Centre.
Three adults with eczema were consulted during
the design phase of the study. As a result of their input
we asked a local doctor to join the steering committee,
subjects were referred to as participants, and the term
“treatment failures” was avoided when communicating
with participants. The protocol was approved by the
local research ethics committee, and written informed
consent was obtained for all participants.
Interventions
We performed a pragmatic, double blind, randomised
controlled trial of 18 weeks’ duration, with follow up
every six weeks. We randomised participants to one of
two treatment groups. Children in the mild arm
received 1% hydrocortisone ointment twice daily for
seven days. Children in the potent arm used 0.1% beta›
methasone valerate (Betnovate; GlaxoWellcome) twice
daily for three consecutive days, followed by a base
emollient only (white soft paraffin) for four days. Both
treatments were dispensed in white tubes labelled A
and B to maintain blinding of the treatment allocation.
The contents of tube A were applied for three days
then tube B for four days. In the mild arm both tubes
contained hydrocortisone whereas in the potent arm
tube A contained betamethasone valerate and tube B
contained the base emollient. Treatment was given in
seven day bursts when required.
Primary outcomes
Primary outcomes were based on reports of scratching
recorded in a daily diary. Scratch scores were graded in
response to “how much has your eczema made you
scratch today?” from 1 (not at all) to 5 (all the time).
Scores of 2 or less were categorised as a scratch›free
period. Participants were assumed to be in relapse if
they scored more than 2 for at least three consecutive
days. The primary outcomes were the number of
scratch›free days and the number of relapses during
the study period. We were unable to find validated
methods for capturing patient defined outcomes.13
Nevertheless, data relating to scratch›free days from
our study had good face validity when developed at a
piloting stage and were acceptable to patients. In addi›
tion, results based on this scale were consistent with
those obtained with the validated secondary outcome
measures for disease severity and quality of life.
Secondary outcomes
Short term control was assessed by comparing the
median duration of the first relapse and the median
duration of the first remission in the two treatment
groups. The number of undisturbed nights was also
recorded in the diary. Disease severity was assessed by
using the six area, six sign atopic dermatitis severity
scale at intervals of six weeks.14 Quality of life was
assessed by using the children’s life quality index and
the dermatitis family impact questionnaire at baseline
and at 18 weeks.15 16 The proportion of treatment
failures in each group was defined as the number of
participants who used concurrent treatments or who
were lost to follow up. Skin thickness was measured at
baseline and at 18 weeks with a 20 MHz B mode ultra›
sound scanner (Longport International, Reading).
Sites scanned were the elbow and knee creases, the lat›
eral aspect of the forearm, and the back of the calf. An
independent assessor took six measurements at fixed
distances along the horizontal edge of each image,
from which the mean skin thickness (epidermis and
dermis) was calculated.
Sample size
To detect a difference of at least 15% in the mean
number of scratch›free days between the two groups,
using a two sample t test with an 0.05 two sided signifi›
cance level and 90% power, we needed a sample size of
89 in each group. Allowing for attrition at 10%, we
needed 100 participants in each group.
Randomisation and blinding
Randomisation was computer generated in blocks of
four. The list was produced and stored by the clinical
trials pharmacist at Queen’s Medical Centre. Treat›
ment packs were prepared and labelled at the
pharmacy. The research assistants used consecutively
numbered packs to allocate new participants to
treatment groups.
Participants and assessors were blinded to group
assignment during collection of the data. At the end of
the study, participants, or parents for younger children,
were asked to guess their treatment group to test the
efficacy of blinding.
Economic evaluation
We evaluated the costs of the two treatments to the
NHS. We included direct costs (ointments and rescue
treatment), consultations with health professionals
(with general practitioners and visits as outpatients and
inpatients), and the use of prescribed drugs or
treatments during the trial. We calculated the quantity
of ointments used by weighing the returned tubes.
Rescue treatment was deemed to be required if partici›
pants dropped out of the study because their eczema
was uncontrolled. For these participants standard care
was assumed on the basis of answers to questionnaires.
Standard care consisted of Eumovate (GlaxoWell›
come) used twice daily for three days, at a cost of 18p.
Costs of prescribed drugs were taken from the
September 2000 edition of the British National Formu›
lary (see table 4). The other costs came from the
Personal Social Services Research Unit for the same
year.17
Statistical methods
We analysed the data before the randomisation code
was broken. Data from the diaries were highly skewed
and remained so despite transformation. These data
were analysed with the non›parametric Mann›Whitney
U test and 95% confidence intervals produced for the
median values with the CIA package 2.0.0 (Trevor
Bryant, University of Southampton). All other analysis
was performed in SPSS version 9.
We analysed severity scores by using a repeated
measures analysis of variance. The proportions of par›
ticipants achieving > 20% improvement in scores at 18
weeks and of those in whom treatment failed were
compared by using ÷2 tests with continuity correction.
We compared changes in quality of life between the
Primary care
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groups by using Student’s t test. Clinically important
thinning of the skin was defined as > 25% reduction in
skin thickness compared with baseline at any of the
predefined sites.
Most of the children (84%) were recruited from the
community. As these participants were more likely to
reflect patients treated in primary care, we concen›
trated our analysis mainly on them. We lodged this
decision with the Cochrane Skin Group and with the
NHS Executive (Trent) before analysis. Assessments of
the primary outcome both included and excluded par›
ticipants recruited from hospital in accordance with
the original protocol.
We conducted our analysis on an intention to treat
basis, and we imputed missing data by carrying forward
the last known value. For the economic data if an activ›
ity was not recorded it was assumed that it had not
occurred, and we recorded a zero cost.
Results
We recruited participants from October 1999 to Octo›
ber 2000 and completed follow up assessments by
March 2001 (figure). Table 1 lists the baseline
characteristics. Major differences in severity were
observed between community and hospital patients at
baseline: 60% and 36%, respectively, had mild disease.
Community patients also had less severe eczema, less
impairment of quality of life, and were less likely to use
potent topical steroids, oral antibiotics, and wet wraps
than hospital patients.
Primary outcomes
The median number of scratch›free days was 118.0 for
the mild group and 117.5 for the potent group (differ›
ence 0.5, 95% confidence interval − 2.0 to 4.0;
P = 0.53). Owing to a possible ceiling effect we
re›examined the data, with scratch›free scored as 1
rather than 1 or 2. This resulted in fewer days reported
as scratch›free (mild group, 73 (58%); potent group, 85
(67%)), although this did not alter significance
(difference 12 ( − 16 to 9) days; P = 0.7).
The number of relapses per patient ranged from 0
to 9. None were reported for 73 (44%) participants
(mild arm, 36; potent arm, 37). If missing values were
imputed as scratch›free days, the sensitivity analysis did
not alter the findings significantly (P = 0.32 and
P = 0.51 for scratch›free days and number of relapses,
respectively).
Secondary outcomes
No differences were observed for any of the secondary
outcomes between the groups (table 2). Repeated
measures analysis of the severity scores showed no
major differences between the groups. Both groups
improved by 2.0›2.5 points compared with baseline
values of 8 or 9. Improvements were achieved by six
weeks and maintained throughout the study. Both
groups had a similar proportion of participants who
showed > 20% improvement in severity (mild arm, 48
(55%); potent arm 49 (56%); P = 1.00). The groups
showed similar improvements in quality of life (table 2).
The proportion of participants who dropped out
of the study or resorted to concurrent treatment was
slightly higher in the mild than potent arm (31 (36%) v
22 (25%), respectively) (11% difference, − 3 to 25;
P = 0.19). In the mild arm, six participants dropped out
owing to uncontrolled eczema, 10 dropped out for
other reasons, and 15 used concurrent treatments but
remained in the study. In the potent arm, three partici›
pants dropped out owing to uncontrolled eczema,
eight dropped out for other reasons, and 11 used con›
current treatments but remained in the study.
Adverse events
Eighteen participants reported adverse events: nine in
the mild group and five in the potent group reported
worse symptoms, and two in the potent group
reported spots or rashes and one reported hair growth.
One patient in the potent group was admitted to hos›
pital with viral encephalitis. None of the patients devel›
oped any clinical evidence of skin thinning. Complete
ultrasound data were available for 106 (51%) patients.
Data were unavailable from 1 April to 31 July 2000
either because the machine was unavailable or because
facilities prevented its use. The mean change in skin
thickness was measured in millimetres at each site. Skin
thickness of the elbow crease at baseline was 0.91 mm
(mean change − 0.04 (SD 0.11) mm) for the mild
group and 0.99 ( − 0.05 (0.14) mm) for the potent
group). Findings were similar at sites on the knee, calf,
and forearm. Eleven participants had a reduction in
skin thickness > 25% at 12 sites (table 3). Four (8%)
had been allocated to the mild group and 7 (12%) to
the potent group (P = 0.7).
Success of blinding
Of those participants who returned the final question›
naire, 39 (26%) guessed their group allocation
Eligible patients contacted
Hospital
(n=222)
Community
(n=1924)
Replied
Hospital
(n=67)
Community
(n=312)
Assessed
Hospital
(n=54)
Community
(n=224)
Exlcuded
Refused
No current
atopic eczema
Hospital
n=7
n=4
n=2
Community
n=42
n=19
n=27
Too severe
Not atopic eczema
DNA
No current
atopic eczema
Hospital
n=9
n=4
n=7
n=1
Community
n=7
n=32
n=8
n=3
Randomised
Hospital
(n=33)
Community
(n=174)
Mild arm
Week 0
Week 6
Week 12
Week 18
Hospital
(n=17)
Community
(n=87)
Hospital
(n=17)
Community
(n=79)
Diaries not returned
(n=9)
Hospital
(n=12)
Community
(n=75)
Hospital
(n=11)
Community
(n=71)
Potent arm
Hospital
(n=16)
Community
(n=87)
Intention to treat
Hospital
(n=17)
Community
(n=81)
Intention to treat
Hospital
(n=16)
Community
(n=84)
Hospital
(n=16)
Community
(n=83)
Hospital
(n=15)
Community
(n=76)
Hospital
(n=14)
Community
(n=76)
Flow of participants through trial
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correctly, 39 (26%) guessed incorrectly, and 74 (48%)
could not guess.
Economic evaluation
Participants in the mild arm used an average of 68 g of
hydrocortisone and those in the potent arm used 33 g
of betamethasone valerate (table 4). Both groups used
similar quantities of emollients (mean 400 g). Total
costs were similar for the two groups. The slightly
higher mean costs for the mild group reflected the
participant admitted to hospital (mean £12.11 v £8.61
for the mild and potent groups, respectively). This dif›
ference was not significant (mean difference £3.51,
− £4.79 to £11.80; P = 0.41). We present the results
both with and without this participant (table 4). We
restricted the evaluation to the minimisation of costs as
it would be meaningless to calculate cost effectiveness
ratios when there is no difference in effects or costs.
We conducted two sensitivity analyses; the first
included only those participants for whom complete
data were available (n = 119). This increased the mean
difference between groups to £7.91 but did not reach
significance. The second analysis explored the cost of
treating the nine participants whose eczema was not
controlled by the study ointments. A sensitivity analysis
that assumed treatment consisted of a consultation
with a doctor plus a 30 g tube of Eumovate made little
difference to either total costs or to the difference in
costs between the two groups (mean difference £4.18).
Discussion
Short bursts of a potent topical steroid is just as
effective as prolonged use of a mild preparation for
treating atopic eczema. This was so for all primary and
Table 1 Baseline characteristics of children recruited from hospital and the community with mild to moderate atopic eczema. Values
are numbers (percentages) unless stated otherwise
Hospital patients Community patients
Mild arm (n=17) Potent arm (n=16) Mild arm (n=87) Potent arm (n=87)
Male 8 (47) 10 (63) 49 (56) 36 (41)
White 14 (82) 15 (94) 77 (89) 79 (91)
Mean (SD) age 5 (3.2) 6 (3.0) 5 (3.8) 6 (4.0)
Family income:
<£7999 2 (12) 2 (13) 10 (12) 8 (9)
>£34 000 3 (18) 4 (25) 16 (18) 17 (20)
Education of main care giver (basic) 9 (53) 5 (31) 35 (40) 34 (39)
Mild eczema 6 (35) 6 (38) 62 (71) 52 (60)
Mean (SD) disease severity* 13.6 (8.7) 16.2 (9.7) 8.2 (6.1) 9.0 (6.3)
Mean (SD) quality of life:
Children’s life quality index 7.6 (6.8) 7.8 (5.9) 5.1 (4.1) 5.6 (4.6)
Dermatitis family impact questionnaire 4.9 (6.1) 4.1 (5.3) 2.5 (3.2) 2.9 (3.9)
Mean (SD) skin thickness (mm):
Elbow (n=141) 0.91 (0.2) 0.99 (0.3) 0.91 (0.2) 0.92 (0.1)
Forearm (n=142) 0.95 (0.2) 0.89 (0.1) 0.95 (0.2) 0.95 (0.1)
Knee (n=127) 1.01 (0.3) 0.98 (0.15) 0.99 (0.2) 1.04 (0.2)
Calf (n=123) 1.08 (0.2) 1.19 (0.2) 1.12 (0.1) 1.16 (0.2)
Mean (SD) areas of involved skin 8.0 (8.1) 7.6 (5.3) 2.5 (2.9) 2.8 (3.2)
Mean (SD) amount of steroid used in past month 15.7 (14.3) 12.8 (15.5) 13.8 (18.5) 14.9 (21.3)
Potent steroids prescribed 14 (88) 14 (88) 19 (23) 23 (27)
Wet wraps used 7 (41) 10 (63) 3 (3) 12 (4)
Antibiotics taken for skin in past year 7 (41) 8 (50) 20 (23) 20 (2)
Oral steroids used 3 (17) 2 (13) 3 (3) 9 (10)
Steroid inhaler used 6 (35) 8 (50) 23 (26) 29 (33)
*According to six area, six sign atopic dermatitis severity scale.
Table 2 Intention to treat analysis of outcome measures of children with mild to moderate atopic eczema treated with short bursts of
a potent topical corticosteroid (potent arm) or continuous use of a mild preparation (mild arm). Secondary outcomes presented for
participants recruited in community only. Values are medians (interquartile ranges) unless stated otherwise
Outcome measure Mild arm Potent arm Difference (95% CI) P value
Primary outcomes
No of scratch›free days:
All participants (n=198) 118.0 (99.8›124.0) 117.5 (99.3›125.0) 0.5 (−3.0 to 2.0) 0.68
Community only (n=165) 118.0 (105.5›124.5) 117.5 (92.3›124.8) 0.5 (−2.0 to 4.0) 0.53
No of relapses:
Community only (n=165) 1.0 (0.0›3.0) 1.0 (0.0›3.0) 0 0.66
Secondary outcomes
Duration of first relapse (n=92)* 4.0 (3.0›7.5) 4.0 (3.0›9.0) 0.0 (−1.0 to 0.0) 0.33
Duration of first remission (n=89)† 6.0 (4.0›20.5) 7.0 (3.0›15.0) −1.0 (−2.0 to 3.0) 0.95
Undisturbed nights (n=165) 123.0 (109.5›126) 121.0 (101.3›126) 2.0 (0.0 to 2.0) 0.53
Mean (SD) change from baseline:
Children’s life quality index (n=168) −2.4 (4.0) −1.9 (3.0) −0.5 (−1.52 to 0.62) 0.41
Dermatitis family impact questionnaire (n=169) −0.5 (2.4) −0.6 (2.2) −0.1 (−0.60 to 0.80) 0.78
*Participants who had relapse.
†Participants who had relapse followed by remission.
Primary care
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secondary outcomes in our study, regardless of
whether community patients or community and hospi›
tal patients were analysed. Symptoms could be control›
led in the community with simple cheap treatments
used at an adequate dosage. Economic evaluation also
showed that both treatments had similar resource
implications.
Impact on skin thinning
Interpretation of the ultrasound data was difficult as
methodological problems exist when this technology is
used within a pragmatic randomised controlled trial.
Location of the scan, time of day, temperature, and
humidity affect skin thickness.18 19 Eczematous skin is
also abnormally thick (lichenified) and much of the
reduction in thickness may be due to a return to
normal levels. We found that eight of the 12 sites with
large reductions in skin thickness had active eczema at
baseline, and in all but two instances baseline skin
thickness was 20%›50% higher than the mean for the
site. The skin thickness after 18 weeks was within the
normal range at baseline for all the participants.
Therefore both mild and potent steroids seem to be
safe when used appropriately over four months.
Patients’ choice of treatment
Following feedback on the results, 50% of the
participants who responded to the questionnaire said
they would choose 1% hydrocortisone; largely because
they preferred to use a mild steroid if it controlled the
eczema successfully. By contrast, 50% chose to use
betamethasone in short bursts as it reduced treatment
time and controlled the eczema quickly. The final
choice of treatment could be left to patients.
Possible explanations
The lack of difference between the mild and potent
groups can be explained in several ways. Firstly, partici›
Table 3 Skin thickness measurements of children treated with short bursts of a potent
topical corticosteroid or continuous use of a mild preparation showing >25% reduction
in skin thickness from baseline
Skin thickness
At baseline At 18 weeks
Elbow crease:
Potent 1.49 0.97
Potent 1.19 0.81
Potent 1.15 0.79
Potent 0.91* 0.66
Knee crease:
Potent 1.25 0.85
Potent 1.30 0.94
Mild 1.27 0.94
Mild 1.28 0.95
Mild 1.18 0.88
Mid›point of forearm:
Mild 1.86 1.36
Back of calf:
Potent 1.35 0.99
Potent 0.95* 0.70
*Normal skin thickness at baseline.
Mean (SD, range) values for sites: elbow crease, 0.92 (0.2, 0.54›1.49); knee crease, 1.02 (0.2, 0.63›1.50);
mid›point of forearm, 0.95 (0.1, 0.65›1.86); back of calf, 1.15 (0.2, 0.69›1.60).
Table 4 Costs of treating 87 children with mild or moderate atopic eczema in each treatment arm with topical corticosteroids for 18
weeks
Unit cost
Mild arm Potent arm
Units £ Units £
Direct costs
Study ointments: 5918.5g 118.37 2857.4g 131.44
Hydrocortisone £0.60/30 g
Betnovate £1.40/30 g
Rescue treatment @ 18p/episode 3 days Eumovate
(GlaxoWellcome) twice daily
6 episodes 1.08 3 episodes 0.54
Total cost 119.45 131.98
Mean (SD) per patient 1.37 (1.4) 1.52 (1.2)
Concurrent eczema treatment
Emollients £6.60/500 g (Diprobase;
Schering›Plough)
35 525 g 468.93 34 668 g 457.62
Topical steroids Individually costed 29 days 6.80 44 days 2.82
Wet wraps 75p/m 0 courses 0 5 courses 3.75
Oral antibiotics £3.68/course 7 courses 25.76 2 courses 7.36
Total cost 501.49 471.55
Mean (SD) 5.76 (8.1) 5.42 (7.9)
Consultations
Doctor £18.00/consultation 8 144.00 7 126.00
Phone call to doctor £21.00/call 1 21.00 1 21.00
Outpatient £53/consultation 0 0 0 0
Inpatient stay £203/night 1 203.00 0 0
Casualty £65/visit 1 65.00 0 0
Total cost 433.00 147.00
Mean (SD) 4.98 (33.3) 1.69 (6.7)
Mean (SD)† 1.50 (7.5) 1.69 (6.7)
Total cost
Direct costs, concurrent treatment costs, and consultation costs 1,053.94 8.63 (12.9) 749.03
Mean (SD) 12.11 (37.0) 8.61 (12.8)
Mean (SD)† 8.39 (12.9) 8.61 (12.8)
Mean difference (95% CI); P value 3.49 (−4.81 to
11.78); 0.41)
*Student’s t test.
†Mean (SD) excluding child admitted to hospital.
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pants were mainly from the community, where disease
severity was skewed towards the mild end. Secondly,
entry into the study and regular contact with the
researcher may have influenced parental concordance
with treatment, resulting in 1% hydrocortisone, which
patients often use for only one or two days, being
applied for seven days.
Care has to be taken when generalising our
findings to clinical practice. Prescribing the prepara›
tions without full instructions may not result in the
clinical improvement we achieved.10 Practice nurses or
nurses specialised in dermatology can help promote
appropriate use.20 Greater care has to be taken when
generalising our findings to secondary care, where
children with severe disease predominate.
Comparison with other studies
No study to date has compared the intermittent use of
mild and potent steroids for mild and moderate atopic
eczema in a pragmatic way. The only published
randomised controlled trial to have considered
intermittent topical treatment was a 16 week study of
54 adults with moderate to severe atopic eczema.21
Once the participants were in remission they were
given either a potent topical steroid or a vehicle for two
days a week for known “healed” lesions. Those in the
active group had a lower risk of relapse than those in
the vehicle group. Two other studies, published as
abstracts, have evaluated time to relapse and intermit›
tent treatment.22 23
Strengths and weaknesses of our study
The strengths of our study include its pragmatic
design, long duration, and the use of patient specific
outcomes alongside validated scales for severity and
quality of life. The study population also reflects a
wider group of patients with eczema than in previous
hospital based studies and is thus better able to inform
general practice, where most cases are treated.
Nevertheless, some reservations exist. In particular, the
median number of scratch›free days was high in both
groups, which could make a further 15% reduction in
symptoms difficult to achieve. Our definition of relapse
may have failed to capture the true morbidity.
Comparison of the number of 7 day treatment blocks
initiated in each group showed that participants
resorted to treatment in the absence of self reported
itch (median 7 treatment blocks initiated in mild
group, 8 in potent group). This contrasts with a median
of one relapse defined by the scratch scores in both
groups.
Recommendations for research
The liberal use of an emollient might achieve similar
control to topical steroids for children with mild or
moderate eczema. Researchers should consider a
treatment arm of emollient only for trials based in pri›
mary care. Relapses could also be defined on the basis
of parents starting treatment rather than as reported
itch.
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